Who owns Regeneron Pharmaceuticals?
Mason Cooper
Published Jun 11, 2026
Who owns Regeneron Pharmaceuticals?
Top 10 Owners of Regeneron Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 7.23% | 7,638,297 |
| BlackRock Fund Advisors | 5.92% | 6,256,868 |
| Capital Research & Management Co…. | 5.03% | 5,320,000 |
| SSgA Funds Management, Inc. | 4.39% | 4,640,005 |
Does Regeneron prevent Covid?
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 | Regeneron Pharmaceuticals Inc.
What does Regeneron Pharmaceuticals Inc do?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
What products do Regeneron make?
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
Is Regeneron FDA approved?
In the U.S. , REGEN-COV has not been approved by the FDA, but is currently authorized under an Emergency Use Authorization (EUA) to treat people with mild to moderate COVID-19 who are at high risk of serious consequences from COVID-19 infection who are either already infected (non-hospitalized) or in certain post- …
What sector is Regeneron?
healthcare sector
Regeneron Pharmaceuticals serves the healthcare sector in the United States.
How long is Regeneron effective?
Nov. 10, 2021 — The pharmaceutical company Regeneron says a clinical trial shows that one dose of its antibody drug reduces an uninfected person’s chances of contracting COVID-19 by 81.6% for up to eight months after the drug is taken, the company said in a news release.
Does Regeneron have side effects?
The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
Is Regeneron a good company?
Regeneron is a good company to work for. They take care of their employees and do community outreach. Comp and benefits are fair as well. Overall it is a solid company.
Is Regeneron a biotech company?
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Did the FDA approve Regeneron?
The FDA revised its emergency use authorization for Regeneron’s COVID-19 antibody cocktail July 30, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
How long do monoclonal antibodies take to work?
To work, we have to give you the drug early, within 10 days from the start of your symptoms. That is so the protein of the virus can bind to the antibody and keep the infection from getting worse. While you may only have mild symptoms now, because you are high risk, your symptoms could get worse quickly.
Who makes Regeneron drug?
Regeneron is merely the developer of the drug. Last year it turned to Swiss pharmaceutical company Roche to scale up its manufacturing capabilities and to take over distribution outside of the United States.
When did Regeneron go public?
About the Regeneron Science Talent Search. The Regeneron Science Talent Search, a program of Society for Science & the Public since 1942, is the nation’s oldest and most prestigious pre-college science competition.
When was Regeneron founded?
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview , near Tarrytown , New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Is Regeneron a pill?
The drugs don’t come in a simple pill, so they wouldn’t typically be available at the average doctor’s office, but a doctor can prescribe them. The mAbs have to be given by an infusion or, if getting an infusion would cause a delay in treatment, the Regeneron treatment can also be given by four subcutaneous injections.
